Cannabinoid receptors and their ligands

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 2-3, 2002, Pages 101-121

  Pertwee, R G ^a   Ross, R A ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2 ARACHIDONOYLGLYCEROL ETHER; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR AGONIST; CANNABINOID; DRUG RECEPTOR; ENDOCANNABINOID; ICOSANOID;

ANIMAL CELL; ANIMAL TISSUE; APPETITE; ASTHMA; CYTOKINE PRODUCTION; DRUG RECEPTOR BINDING; ENZYME DEGRADATION; GLAUCOMA; HYDROLYSIS; INFLAMMATION; LIGAND BINDING; MEMBRANE TRANSPORT; MOUSE; MULTIPLE SCLEROSIS; NEUROCHEMISTRY; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SPASTICITY; SPINAL CORD INJURY; VASODILATATION; VOMITING; ANIMAL; DRUG POTENTIATION; ENZYME SPECIFICITY; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ANIMALIA;

ANIMALS; CANNABINOIDS; EICOSANOIDS; ENDOCANNABINOIDS; HUMANS; LIGANDS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; SYNAPTIC TRANSMISSION;

EID: 0036019382     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2001.0341     Document Type: Article

References (212)

1. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
2. Molecular characterization of a peripheral receptor for cannabinoids
3. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
4. Endocannabinoids
5. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
6. 2-Arachidonoylglycerol and the cannabinoid receptors
7. 1 receptor
8. Pharmacology of cannabinoid receptor ligands
9. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide
10. Anandamide hydrolysis by human cells in culture and brain
11. Structural determinants for recognition and translocation by the anandamide transporter
12. Biosynthesis and inactivation of endocannabinoids: Relevance to their proposed role as neuromodulators
13. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes
14. The fatty acid amide hydrolase (FAAH)
15. Structure-activity relationships of anandamide, an endogenous cannabinoid ligand
16. 2 receptors
17. Advances in cannabinoid receptor pharmacology
18. Cannabinoid receptors and pain
19. Cellular signal transduction by anandamide and 2-arachidonoylglycerol
20. 2+ signals in cerebellar granule neurons in culture
21. 2+ transient in NG108-15 cells
22. 2+ in neuroblastoma x glioma hybrid NG 108-15 cells
23. 1 receptors in a smooth muscle cell line
24. 1 cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein FAN
25. Ceramide: A new second messenger of cannabinoid action
26. + channels
27. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system
28. s linkage to the CB1 receptor
29. 1 receptor
30. s proteins in cultured hippocampal neurons
31. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: Evidence for agonist-specific trafficking of intracellular responses
32. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices
33. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons
34. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons
35. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons
36. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum
37. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens
38. Effects of anandamide on cannabinoid receptors in rat brain membranes
39. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions
40. 2 receptors
41. 2+++ currents by reversal of tonic CB1 cannabinoid receptor activity
42. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine
43. Inhibitory effects of SR141716A on G-protein activation in rat brain
44. Inhibition of hippocampal acetylcholine release by cannabinoids: Reversal by SR141716A
45. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus
46. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A
47. 1 receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo
48. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor
49. 2 cannabinoid receptors of L759633, L759656 and AM630
50. 8-tetrahydrocannabinol at cannabinoid receptors
51. Imaging the brain marijuana receptor: Development of a radioligand that binds to cannabinoid CB1 receptors in vivo
52. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
53. The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets
54. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281
55. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices
56. 1 ligands in the isolated guinea-pig ileum
57. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: A potential human SPECT ligand
58. Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development
59. 1 vanilloid receptor 'hybrid' ligands
60. Structure-activity relationships among N-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter
61. Effects of cannabinoids on the immune system and central nervous system: Therapeutic implications
62. Cannabinoid receptors and the regulation of immune response
63. 9-tetrahydrocannabinol in rats
64. 9-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration
65. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA
66. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A
67. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices
68. Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374)
69. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes
70. 1 receptors
71. 1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice
72. 1 receptor-deficient mice
73. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus
74. 1 cannabinoid receptors
75. 1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain
76. Cannabinoid receptor-mediated inhibition of dopamine release in the retina
77. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship
78. 1 receptors on peripheral sympathetic nerves
79. 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-adrenoceptors in mouse tissues
80. 3H]noradrenaline from mouse cultured sympathetic neurons: Release-modulating heteroreceptors
81. Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum
82. Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro
83. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus
84. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons
85. A synaptic transmission in the hippocampus
86. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations
87. 1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons
88. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals
89. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist
90. Occlusion of the presynaptic action of cannabinoids in rat substantia nigra pars reticulata by cadmium
91. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro
92. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells
93. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro
94. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: A comparison with opioids
95. Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens
96. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons
97. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures
98. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity
99. 9-Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture
100. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons
101. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells
102. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells
103. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum
104. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata
105. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord
106. 1 receptors at synaptic terminals in cultured cerebellar granule cells
107. Cannabinoid signaling in cultured rat cerebellar granule cells
108. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids
109. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2
110. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus
111. The activation of carmabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake
112. Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice
113. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain
114. 1 receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study
115. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
116. A new perspective on cannabinoid signalling: Complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain
117. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation
118. 1
119. Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus
120. 1 receptor distribution in the myenteric plexus
121. 1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system
122. 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis
123. 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex
124. 9-tetrahydrocannabinol in the nucleus accumbens of rat: An in vivo microdialysis study
125. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra
126. 9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors
127. 1 opioid receptor mechanism
128. 1 receptors
129. Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain
130. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: An in vitro electrophysiological study
131. 9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: A microdialysis study
132. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: An in vivo and in vitro study
133. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
134. A second endogenous cannabinoid that modulates long-term potentiation
135. The neurobiology and evolution of cannabinoid signalling
136. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry
137. Sensitive determination of anandamide in rat brain utilizing a coupled-column HPLC with fluorimetric detection
138. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404
139. 1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland
140. Pain modulation by release of the endogenous cannabinoid anandamide
141. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
142. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
143. Endocannabinoids control spasticity in a multiple sclerosis model
144. Leptin-regulated endocannabinoids are involved in maintaining food intake
145. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease
146. Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide
147. 2 receptor responses by an anandamide transport inhibitor
148. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homolognes
149. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity
150. Interactions between synthetic vanilloids and the endogenous cannabinoid system
151. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
152. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
153. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens
154. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation
155. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase
156. Induction of vanilloid receptor channel activity by protein kinase C
157. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries
158. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed
159. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
160. Cannabinoid inhibition of the capsalcin-induced calcium response in rat dorsal root ganglion neurones
161. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide
162. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity
163. The anandamide transport inhibitor AM404 activates vanilloid receptors
164. The anandamide transport inhibitor AM404 is an agonist at the rat vanilloid receptor (VR1)
165. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
166. Control of pain initiation by endogenous cannabinoids
167. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction
168. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands
169. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor
170. 2 cannabinoid, as potential ligands for the cannabinoid receptors
171. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide
172. 2-like cannabinoid receptors on peripheral nerve terminals
173. Mesenteric vasodilation mediated by endothelial anandamide receptors
174. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors
175. Endocannabinoids as cardiovascular modulators
176. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing
177. Characterization of two cloned human CB1 cannabinoid receptor isoforms
178. 9-THC and cannabinoid (CB1) receptor gene expression in mice
179. Orphan G protein-coupled receptors in the CNS
180. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A
181. 9-THC and anandamide
182. 9-THC-induced antinociception
183. 2 receptor-mediated actions of anandamide in mouse brain
184. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain
185. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
186. Anandamide antagonism: Do pharmacokinetics play a role?
187. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain
188. The biodisposition and metabolism of anandamide in mice
189. Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice
190. Oxidative metabolism of anandamide
191. 2 ethanolamide from anandamide by cyclooxygenase-2
192. 2α, a naturally occurring substance
193. 2 cannabinoid receptors in rat brain and human tonsils
194. 2 ethanolamide
195. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2
196. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist
197. Anandamide hydroxylation by brain lipoxygenase: Metabolite structures and potencies at the cannabinoid receptor
198. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): Their affinities for cannabinoid receptors and pathways of inactivation
199. Direct activation of capsaicin receptors by products of lipoxygenases: Endogenous capsaicin-like substances
200. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism
201. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus
202. Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel
203. Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase
204. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
205. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation
206. Marijuana smoking vs cannabinoids for glaucoma therapy
207. Cannabinoid transmission and pain perception
208. 1 receptors mediate the vasodilated state in advanced liver cirrhosis
209. Cannabinoids and multiple sclerosis
210. Effective treatment of Tourette's syndrome with marijuana
211. Cannabis in movement disorders
212. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol